← Back
Data updated: Jun 28, 2026
SENTYNL THERAPS INC
Pharma Pharmaceuticals
SENTYNL THERAPS INC is a pharmaceutical company with 4 FDA-approved products.
2011
Since
4
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
3 Small Molecules
FDA Novel Drug Designations
(2020-2021) 2 Novel 2 First-in-Class 2 Orphan 2 Breakthrough 2 Priority Review
SENTYNL THERAPS INC's Key Drugs
SENTYNL THERAPS INC's core commercial portfolio centers on ZOKINVY, ZYCUBO, NULIBRY — its most strategically important drugs approved in the last 15 years.
SENTYNL THERAPS INC's Recent FDA Approvals
SENTYNL THERAPS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SENTYNL THERAPS INC's Therapeutic Areas
Disease areas where SENTYNL THERAPS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SENTYNL THERAPS INC Pipeline Snapshot
Active clinical trials for SENTYNL THERAPS INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZOKINVY leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling